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Abstract: To investigate the value of the annual follow-up neck
ultrasonography (US) for postoperative surveillance in patients with
papillary thyroid microcarcinoma (PTMC).
This retrospective study has been approved by our institutional
review board (IRB) with waiver for informed consent. A total of 375
patients diagnosed as PTMCs, who underwent total thyroidectomy with
radioiodine remnant ablation were included, to identify the recurrence
rate and the false-positive rate of annual ultrasound. The number,
interval, and the results of follow-up US or fine needle aspiration were
obtained from electronic medical records.
Four (1.1%, 4/375) recurrences were found 3 years after the initial
treatment, and only 1 patient (0.3%, 1/375) had a metastatic lymph node
larger than 8mm in the shortest diameter on US found 7.6 years after
initial treatment with biochemical abnormalities. Cumulative risk of
having at least 1 false-positive exam was 8.3% by the 8th US, and 8.1%
by the 8–9 year follow-up. Cox multivariate regression showed shorter
interval of follow-up US and presence of lymph node metastasis at
initial surgery are independent predictors affecting the cumulative false-
positive results (hazard ratio [HR], 0.60; 95% confidence interval [CI]:
0.49–0.73; P< 0.001 and HR, 2.19; 95% CI: 1.01–4.75; P¼ 0.048,
respectively).
Short-term follow-up US can result in higher cumulative false-
positive results without detection of meaningful recurrences in patients
with PTMCs who do not have biochemical abnormalities.
(Medicine 95(1):e2435)
Abbreviations: CI = confidence interval, DTC = differentiatedKyung Kim, MD, P ouk, MD, PhD,
D, PhD, and Jin Young Kwak, MD, PhD
INTRODUCTION
E ver since Pacini et al
1 suggested that the recombinant human
thyroid-stimulating hormone (rhTSH)-stimulated thyroglo-
bulin (Tg) measurement and neck ultrasonography (US) is a
superior combination to rhTSH-stimulated Tgmeasurement and
131I whole body scan in the postoperative surveillance of
patients treated with differentiated thyroid cancers (DTCs),
US has been widely accepted as the standard follow-up imaging
modality for patients with DTCs.2 The combination of stimu-
lated Tg and neck US showed sensitivity of up to 100% for
diagnosing recurrences in patients with DTCs.3 US is a highly
sensitive diagnostic tool that detects locoregional recurrences in
the neck, which is the most common site of recurrence for
thyroid cancers,1,4,5 detecting recurrences even when abnorm-
ality of Tg levels have not been identified.5–7 However, the
clinical value of US surveillance is uncertain for patients with
papillary thyroid microcarcinomas (PTMCs), because most
PTMCs have an indolent clinical course, and the tumor recur-
rences come in small volumes that may not affect overall
survival of the patient, in which treatment may cause more
morbidity than its natural disease progression.8–10
The primary goal of postoperative surveillance is to detect
clinically significant recurrences, not to reveal all indolent
lesions. The 2015 American Thyroid Association (ATA) guide-
lines do not recommend fine-needle aspiration (FNA) for very
small-sized lymph nodes detected on postoperative surveillance
US, even when abnormal US features are observed.2 Although
annual US is generally recommended for 3 to 5 years as
postoperative surveillance for patients with DTCs,11 we came
to wonder how annual US performed for postoperative surveil-
lance may have impact on PTMC patients after surgery. There-
fore, we investigated the value of annual follow-up neck US for
postoperative surveillance in patients with PTMCs, evaluating
the frequency of locoregional recurrences detected on US, and
the false-positive rates.
METHODS
Study Cohort
Our institutional review board (IRB) approved of this
retrospective study, and the requirement to obtain informed
consent was waived. From January 2003 to December 2006,
1486 patients were confirmed to have PTMCs. Total thyroid-
ectomy with radioiodine remnant ablation treatment was per-
formed in 421 patients. Prophylactic central lymph node
dissections were routinely performed at our institution. Of
the 421 patients, 46 patients were excluded from the study; 9
for not receiving a follow-up for at least 36 months, 2 due toer and breast cancer, respectively, and 35
e anti-Tg antibody. Finally, 375 patients
en) were included (Figure 1). The mean
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FIGURE 1. Flow chart of the study group, aNo structural recurrence, but increased serum thyroglobulin level on final follow-up in 2
patients, and follow-up loss in 2 patients after diagnosis of biochemical recurrence. bThe patient had a normal serum thyroglobulin level on
Yoon et al Medicine  Volume 95, Number 1, January 2016age at surgery was 48.5 years (standard deviation [SD], 10
years; median age, 48 years; range, 20–78 years). The mean
size of the 375 PTMCs was 6.3mm (SD, 2.1mm; median size,
6mm; range, 2–10mm).
Follow-Up Protocol
All patients underwent thyroid-stimulating hormone
(TSH)-suppressive therapy with levothyroxine after surgery
and were followed every 6 months for the first 3 years after
initial treatment and then yearly afterward. For these patients,
we recommended clinical examinations for every 6 months,
neck US, chest X-ray, and measurements of serum TSH, free
T4, Tg, and anti-Tg antibody for every 12 months.12 Whole
body scan, chest computed tomography (CT), magnetic reson-
ance imaging (MRI), or fluorodeoxyglucose positron emission
tomography (PET) was performed only in selective cases (eg,
detectable serum Tg or persistent anti-Tg antibody without
evident recurrence on US or whole body scan).
Before 2011, monoclonal antibody immunoradiometricas-
say (IRMA; CIS Bio International, Gif-sur-Yvette, France) was
used for serum Tg level assays.13 Radioimmunoassay was used
for measuring serum anti-Tg antibodies (Brahms, Hennigsdorf/
Berlin, Germany, functional sensitivity of 10 IU/mL: positive
defined as value exceeding 60U/mL), and serum TSH levels
(Trinity Biotech, Co. Wicklow, Ireland, reference range of 0.4–
3.1mIU/mL, functional sensitivity of 0.0038mIU/L). From
2011 to the present, electrochemiluminescence immunoassay
using the Cobas e601 immunoassay analyzer (Roche Diagnos-
tic, Mannheim, Switzerland) was used for serum Tg level assay
final follow-up.(functional sensitivity, defined by the lowest analyte concen-
tration that can be reproducibly measured with a precision CVof
20%, was 0.1 ng/mL). Serum TSH levels were measured by a
2 | www.md-journal.comchemiluminescence immunoassay with an automated immu-
noassay analyzer (Architect i2000, Abbott Laboratories, Abbott
Park, IL, reference range: 0.35–4.94mIU/mL, functional sen-
sitivity of 0.01mIU/mL).
Neck US was performed using a 5- to 15-MHz linear array
transducer (HDI 5000 or 3000, Philips-Advanced Technology
Laboratories, Bothell, WA; iU22, Philips Medical Systems;
Logic 9, GE Medical Systems, Milwaukee, WI; Acuson
Sequoia 512, Siemens Medical Solutions USA, Inc, Mountain
View, CA; EUB-7500, Hitachi Medical, Tokyo, Japan) by 77
radiologists, including 3 faculties who specialized in thyroid
imaging, 15 faculties of other specialties, 4 fellows, and 55
residents of the radiologic department. When a lymph node
showed loss of fatty hilum, diffuse or focal hyperechogenicity,
cystic change, microcalcifications, round shape, or chaotic or
peripheral vascularity on US, we regarded it as an abnormal
lymph node.14 Although the follow-up protocol is specifically
defined at our institution, a detailed follow-up interval that
differs from the institutional guidelines has been chosen at the
discretion of the physician or the preference of each
individual patient.
Recurrence
No clinical evidence of disease was defined as suppressed
Tg< 1 ng/mL, stimulated Tg< 2 ng/mL, no detectable anti-Tg
antibody, or no evidence of disease on US, CT,MRI, PET/CT, or
whole body scan at final follow-up. Persistence was defined as
suppressed Tg 1 ng/mL or stimulated Tg 2 ng/mL, or any
evidence of disease on US, CT, MRI, PET/CT, or whole body
scan after initial surgery and radioiodine remnant ablation
therapy. Recurrence was defined as ‘‘malignancy’’ on cytology
results, elevated serum Tg or uptake on whole body scan in
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.
TABLE 1. Characteristics of the Study Cohort
Characteristic
Age (years, meanSD) 48.5 10
Gender
Male 42 (11.2%)
Female 333 (88.8%)
Primary tumor
Pathologic size (mm, meanSD) 6.3 2.1
Multifocality in 1 lobe 36 (9.6%)
Bilaterality 96 (25.6%)
Extrathyroidal extension 180 (48%)
Lymph node metastasis
Central LNM 107 (28.5%)
Lateral LNM 22 (5.9%)
Distant metastasis 1 (0.3%)
AJCC/UICC staging
I 225 (60%)
III 137 (36.5%)
Iva 13 (3.5%)
RAI ablation
30mCi 365 (97.3%)
60mCi 8 (2.1%)
90mCi 1 (0.3%)
150mCi 1 (0.3%)
ATA risk stratification
Low-risk 141 (37.6%)
Intermediate-risk 232 (61.9%)
High-risk 2 (0.5%)
Status at final follow-up
No evidence of disease 366 (97.6%)
Structural persistence 1 (0.3%)
Biochemical persistence and structural recurrence 1 (0.3%)
Biochemical recurrence 4 (1%)
Biochemical and structural recurrence 1 (0.3%)
Structural recurrence 2 (0.5%)
AJCC/UICC TNM staging¼ the American Joint Committee on
Cancer (AJCC)/Union Internationale Contre le Cancer (UICC) staging
(7th ed., 2010). ATA¼American Thyroid Association, LNM¼ lymph
Follow-Up US in PTMCpatients with no clinical evidence of disease. US-guided FNA
(US-FNA) was usually performed for a suspected recurrent
mass on US. Cytopathologic results were obtained by US-FNA
and surgical excision.
Data and Statistical Analysis
Regarding follow-up US after complete treatment, we
comprehensively reviewed the number, interval, and the result
of follow-up US, using electronic medical records. If US-FNA
was performed to diagnose focal lesions of the neck, these
results were also recorded. Relevant data of the included
patients were obtained for recurrences or patient mortality from
our institution database.
Positive US results were considered true-positive if any
atypical or malignant cells were seen on either cytology or
pathology. Positive US results were considered false-positive if
no atypical or malignant cells were seen on cytology or if the
lesion was not visible on the final follow-up US which was
performed at least 1 year after the prior follow-up showing
positive results. Regarding cases with structural persistence or
recurrence as true-positives, we estimated the cumulative risk of
false-positive results on follow-up US based on both time-to-
event and tests-to-event using the Kaplan–Meier approach.15
Patients who had false-positive or true-positive results were no
longer included in the Kaplan–Meier analysis despite the
ongoing examinations performed afterwards.
Cox proportional hazards models were used to evaluate
factors affecting the cumulative risk of false-positive results on
follow-up US by univariate analysis. Multivariate analysis was
performed after adjustment for baseline characteristics and
known prognostic factors. Firth correction was applied because
large point estimates were for the covariate ‘‘Dose of RAI’’
(radioactive iodine). Two-sided P value< 0.05 was considered
to indicate statistical significance. Statistical analyses were
performed using a computerized statistics program (SAS ver-
sion 9.2 for Windows; SAS Institute, Cary, NC) and R package,
version 3.1.1 (http://www.R-project.org).
RESULTS
Clinical characteristics are presented in Table 1. None of
the patients in the study population died during the study period.
Mean follow-up duration from initial treatment to the last
clinical follow-up was 98.8 months (SD, 19.6 months; median,
98.5 months; range, 36.8–141.9 months). During follow-up,
1.1% (4/375) of the patients had structural recurrences, 0.3% (1/
375) had structural persistence, and 1.1% (4/375) had bio-
chemical recurrences (Table 2). All recurrences were detected
3 years after the initial treatment. Of the 4 patients with
structural recurrences, 2 had elevated serum Tg levels that
was normalized after surgery, and 2 had normal serum Tg
levels among which 1 had surgery and was disease-free at final
follow-up, and the other patient was followed without any
changes observed during follow-up. Among the 4 patients with
biochemical recurrence, 2 had stable serum Tg levels during
follow-up, and the remaining 2 were lost for follow-up. One
patient with structural persistence underwent surgery and was
disease-free at final follow-up.
There were 33 patients (8.8%, 33/375) who had one or
more abnormal focal lesion(s) detected on postoperative sur-
veillance US (Appendix, http://links.lww.com/MD/A599).
Medicine  Volume 95, Number 1, January 2016Most of them (72.7%, 24/33) showed loss of fatty hilum or
other nonspecific US features. US-FNAs were performed on 28
focal lesions of 25 patients, and 5 patients (15.2%, 5/33) were
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.diagnosed as metastasis. Among the focal lesions, only 1
measured larger than 8mm at the shortest diameter.
During the study period, 2346 neck US were performed for
postoperative surveillance (Table 3). For the 375 patients, the
median number of neck US examinations obtained was 6
(range, 1–14). Among the 375 patients who were examined
by neck US, 8.3% (28/375) had at least 1 false-positive US
(Table 3). The cumulative risks of having at least 1 false-
positive exams were 8.3% by the 8th US and 8.1% by the 8
to 9 year follow-up. After that, the cumulative risk of having at
least 1 false-positive exam did not increase.
We evaluated the factors affecting the cumulative risk of
false-positive results on follow-up US (Table 4). On univariate
analysis, the shorter interval of follow-up US (hazard ratio
[HR], 0.60; 95% confidence interval [CI]: 0.50–0.73;
P<0.001) and LNM (HR, 2.4; 95% CI: 1.15–5.06;
node metastasis, RAI¼ radioactive iodine, SD¼ standard deviation.P¼ 0.02) were statistically significant factors affecting the
cumulative false-positive results on follow-up US. Cox multi-
variate regression analysis showed that the shorter interval of
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TABLE 3. Cumulative Probability of a First False-Positive Result by Number of Neck USs Performed and by Follow-Up Year in 375
Patients
Number of
Neck USs
Number
Exams, %
Cumulative
Number
Exams, %
Number of
False-Positive
Results
Number of
True-Positive
Results
Cumulative
False-Positive
Results (SE), %
1 375 (100) 375 (16.98) 5 1 1.33 (0.59)
2 368 (98.1) 743 (31.67) 5 0 2.67 (0.83)
3 360 (96) 1103 (47.02) 10 1 5.38 (1.17)
4 336 (90) 1439 (61.34) 3 1 6.22 (1.26)
5 302 (80.5) 1741 (74.21) 4 1 7.46 (1.39)
6 243 (64.8) 1984 (84.57) 0 1 7.46 (1.39)
7 161 (42.9) 2145 (91.43) 0 0 7.46 (1.39)
8 107 (28.5) 2252 (95.99) 1 0 8.33 (1.62)
9 60 (16) 2312 (98.55) 0 0 8.33 (1.62)
10 21 (5.6) 2333 (99.45) 0 0 8.33 (1.62)
11 7 (1.9) 2340 (99.74) 0 0 8.33 (1.62)
12 3 (0.8) 2343 (99.87) 0 0 8.33 (1.62)
13 2 (0.5) 2345 (99.96) 0 0 8.33 (1.62)
14 1 (0.3) 2346 (100) 0 0 8.33 (1.62)
Duration,
year
Number
Subjects, %
Cumulative
Number
Subjects, %
Number of
False-Positive
Results
Number of
True-Positive
Results
Cumulative
False-Positive
Results (SE), %
0–1 295 (78.67) 295 (12.57) 5 1 1.34 (0.59)
1–2 316 (84.27) 611 (26.04) 1 0 1.61 (0.65)
2–3 306 (81.6) 917 (39.09) 9 0 4.03 (1.02)
3–4 299 (79.74) 1216 (51.83) 7 2 5.94 (1.23)
4–5 283 (75.47) 1499 (63.9) 4 1 7.08 (1.34)
5–6 234 (62.4) 1733 (73.87) 1 0 7.37 (1.37)
6–7 218 (58.14) 1951 (83.16) 0 0 7.37 (1.37)
7–8 190 (50.67) 2141 (91.26) 0 1 7.37 (1.37)
8–9 112 (29.87) 2253 (96.04) 1 0 8.13 (1.55)
9–10 68 (18.14) 2321 (98.93) 0 0 8.13 (1.55)
10–11 22 (5.87) 2343 (99.87) 0 0 8.13 (1.55)
Medicine  Volume 95, Number 1, January 2016 Follow-Up US in PTMCfollow-up US and lymph node metastasis are independent
11–12 3 (0.8) 2346 (100)
SE¼ standard error.predictors affecting the cumulative false-positive results on
follow-up US (HR, 0.60; 95% CI: 0.49–0.73; P<0.001 and
HR, 2.19; 95% CI: 1.01–4.75; P¼0.048, respectively).
DISCUSSION
In this study of patients with PTMCs who underwent total
thyroidectomy and radioiodine remnant ablation treatment,
locoregional structural recurrence was detected in 1.1% (4/
375) of patients at a median follow-up of 98.5 months. Con-
sidering the clinical insignificance of small lymph nodes, even
with cancer foci, the 2015 ATA guidelines suggest performing
US-FNA for suspicious lymph nodes of 5 to 8mm in the
smallest diameter.2 When considering the size cut-off for
diagnostic FNA in lymph nodes, only 1 (0.3%) patient had a
metastatic lymph node measuring larger than 8mm in the
shortest diameter on US in this study, who had biochemical
recurrence. There were no significant structural recurrences
detected among patients without biochemical recurrences.The goal of postoperative surveillance is to properly detect
recurrences which can affect morbidity and mortality from the
disease, while minimizing unnecessary invasive biopsies and
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.patient anxiety. Although several guidelines recommend peri-
odic US with serum Tg assessments as postoperative surveil-
lance for patients with DTC, these guidelines do not provide an
optimal time length of follow-up intervals for postoperative
surveillance US,2,16 and annual US has been performed emperi-
cally for postoperative surveillance.4,5,17 Recently, false-
positive abnormalities have been reported to result from fre-
quent neck US of patients with intermediate risk for PTC.18 In
this study, shorter follow-up US intervals and lymph node
metastasis at initial surgery resulted in a higher cumulative
false-positive results on follow-up US. Also, all 4 structural
recurrences were found 3 years after initial treatment, and 1
metastatic lymph node measuring larger than 8mm in the
shortest diameter was found on US performed 7.6 years after
the initial treatment. From our results, we can conclude that the
frequent use of highly sensitive US may lead to overuse of
invasive procedures such as US-FNA, and cause subsequent
psychological distress or economic burden on patients, despite
of the lack in established benefits. On the other hand, negative
results on follow-up US can lessen patient anxiety that should
0 0 8.13 (1.55)not be neglected, but as there are no consensus on which interval
or duration that postoperative surveillance US should be per-
formed, we expect our results to be a start of future prospective
www.md-journal.com | 5
TABLE 4. Factors Affecting the Cumulative Risk of False-Positive Results in Follow-upUS by Cox Regression Analysis Using the Firth
Correction Method
Univariable Multivariable
Characteristic HR (95% CI) P Value HR (95% CI) P Value
US follow-up interval 0.60 (0.50–0.73) <0.001 0.60 (0.49–0.73) <0.001
Age
45 1.17 (0.53–2.59) 0.692 1.20 (0.54–2.66) 0.659
<45 1 [Reference] 1 [Reference]
Gender
Male 2.29 (0.93–5.64) 0.073 1.64 (0.66–4.08) 0.293
Female 1 [Reference] 1 [Reference]
Pathologic size, mm
5 0.98 (0.40–2.41) 0.96 0.77 (0.30–1.94) 0.578
<5 1 [Reference] 1 [Reference]
Extrathyroidal extension
Positive 0.81 (0.38–1.71) 0.577 0.98 (0.46–2.09) 0.948
Negative 1 [Reference] 1 [Reference]
LNM
Positive 2.41 (1.15–5.06) 0.02 2.19 (1.01–4.75) 0.048
Negative 1 [Reference] 1 [Reference]
Dose of RAI 0.64 (0.04–10.99) 0.756 0.55 (0.03–10.20) 0.688
tasta
Yoon et al Medicine  Volume 95, Number 1, January 2016studies providing evidence for more cost-effective surveillance
programs for PTMC patients.
Lymph node metastasis has been reported to be up to
64.1% in the central compartment and 44.5% in the lateral
compartment in patients with PTMCs, when prophylactically
dissected.19 Another issue to contemplate is that the recurrence
and persistence after surgery can be intermingled at both the
central and lateral compartments of the neck, because prophy-
lactic compartment dissection is not universally accepted as
most lymph node metastases are regarded clinically insignif-
icant.20 Until now, there has been no worldwide consensus on
suspicious US features that are suggestive of metastatic cervical
lymph nodes.1,6,21–24 In a study including patients with low risk
thyroid cancers (stage I or II), all recurrences of 44 patients
(8.9%) were identified in the neck, among which 30 patients
(6.1%) had recurrences detected by applying sensitive US
criteria. A substantial portion (70.7%) of recurrences occurred
in the first 5 years after surgery.23 Among the 149 aspirated
lymph nodes, 80.5% (120/149) had benign results on cytology,
which signifies a large number of false-positive findings on US.
It is unclear how many neck recurrences would be clinically
meaningful because the size of the recurrences were not avail-
able.23 Nixon et al25 showed a very low recurrence rate of 0.6%
(5/889) after applying specific US features in diagnosing locor-
egional recurrences in patients who underwent thyroid lobect-
omy for DTC. Durante et al4 also demonstrated that there were
no locoregional recurrences when applying the size criterion of
5mm on a short axis with sensitive US criteria during a median
follow-up of 6.7 years in 312PTMCpatientswithT1N0M0 stage.
These contradictory results may be due to different primary
cancer staging, different US criteria for FNA, and differences
in size criteria for applying US-FNA at focal lesions in the
CI¼ confidence interval, HR¼ hazard ratio, LNM¼ lymph node meneck.4,23 The majority of false-positive results in this study were
from the loss of fatty hilum within cervical LNs detected on US.
The loss of fatty hilum is a highly sensitive feature but with low
6 | www.md-journal.comspecificity, which the 2015 ATA guideline does not consider a
significant finding in assessing metastatic LNs;2 therefore, there
were no additional false-positive results at follow-up US. In
addition, we can understand how different guidelines on abnor-
mal US features of cervical lymph nodes can have impact on the
recurrence rates in patients with thyroid cancers.
There are some limitations to our study. First, this study is
of a retrospective design and the exclusion of some cases was
inevitable. Also, the interval or duration of follow-up US was
not strictly controlled, which may have affected the cumulative
false-positive rates of this study. Second, we included patients
with PTMCs who underwent total thyroidectomy, bilateral
prophylactic central neck dissections, and radioiodine remnant
ablation treatment. Future studies investigating the role of
follow-up US on patients who have been treated less aggres-
sively are anticipated to validate our results. Third, surveillance
US was performed by 77 radiologists with variable experiences.
Although this reflects data obtained from everyday practice, the
quality of US may have been affected. Last, the radiologists
were not blinded to the pathology results of the patient, such as
tumor stage or LN status, which was not considered in analysis.
In spite of these limitations, results of this study suggest
that short-term follow-up US can result in higher cumulative
false-positive results without detection of meaningful
recurrences in patients with PTMCs who do not have
biochemical abnormalities.
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